This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, J. H. Articles by Levine, E. A. Search for Related Content PubMed PubMed Citation Articles by Stewart, J. H., IV Articles by Levine, E. A.

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions

Surgical Oncology Service, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157

Correspondence: Address correspondence and reprint requests to: Edward A. Levine, MD; E-mail: elevine{at}wfubmc.edu.

ABSTRACT

Natural history studies have shown that peritoneal carcinomatosis is uniformly fatal, with a median survival in the range of approximately 6 months. For more than a decade, a handful of centers have pursued aggressive intraperitoneal cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy as an alternative approach to this disease. Strict selection criteria, variation in intraperitoneal chemotherapy, and the vagaries of what represents "cytoreductive surgery" make many of our colleagues, particularly those in medical oncology, reticent to refer patients for such an aggressive therapy. This article establishes a conceptual framework for understanding the role of intraperitoneal hyperthermic chemotherapy in the treatment of peritoneal surface malignancy. This procedure continues to make advancements in the oncological community despite formidable challenges. The advancement of centers of excellence and the initiation of further phase II trials will help to define the optimal treatment approach for peritoneal carcinomatosis.

Key Words: Peritoneal dissemination • Carcinomatosis • Intraperitoneal hyperthermic chemotherapy • Mitomycin C • Cytoreductive surgery

This article has been cited by other articles:

				J. H. Stewart IV, P. Shen, G. Russell, J. Fenstermaker, L. McWilliams, F. M. Coldrun, K. E. Levine, B. T. Jones, and E. A. Levine A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers Ann. Surg. Oncol., August 1, 2008; 15(8): 2137 - 2145. [Abstract] [Full Text] [PDF]

				R. P. McQuellon, G. B. Russell, P. Shen, J. H. Stewart IV, W. Saunders, and E. A. Levine Survival and Health Outcomes After Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Appendiceal Origin Ann. Surg. Oncol., January 1, 2008; 15(1): 125 - 133. [Abstract] [Full Text] [PDF]

				D. Baratti, S. Kusamura, D. Nonaka, G. D. Oliva, B. Laterza, and M. Deraco Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Ann. Surg. Oncol., October 1, 2007; 14(10): 2790 - 2797. [Abstract] [Full Text] [PDF]

				D. Baratti, S. Kusamura, A. Martinetti, E. Seregni, B. Laterza, D. G. Oliva, and M. Deraco Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Ann. Surg. Oncol., August 1, 2007; 14(8): 2300 - 2308. [Abstract] [Full Text] [PDF]

				R. P. McQuellon, S. C. Danhauer, G. B. Russell, P. Shen, J. Fenstermaker, J. H. Stewart, and E. A. Levine Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis Ann. Surg. Oncol., March 1, 2007; 14(3): 1105 - 1113. [Abstract] [Full Text] [PDF]

				J. Michalakis, S. D. Georgatos, E. de Bree, H. Polioudaki, J. Romanos, V. Georgoulias, D. D. Tsiftsis, and P. A. Theodoropoulos Short-Term Exposure of Cancer Cells to Micromolar Doses of Paclitaxel, with or without Hyperthermia, Induces Long-Term Inhibition of Cell Proliferation and Cell Death In Vitro Ann. Surg. Oncol., March 1, 2007; 14(3): 1220 - 1228. [Abstract] [Full Text] [PDF]

				D. Baratti, S. Kusamura, A. Martinetti, E. Seregni, D. G. Oliva, B. Laterza, and M. Deraco Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion Ann. Surg. Oncol., February 1, 2007; 14(2): 500 - 508. [Abstract] [Full Text] [PDF]